Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. (December 2015)

• Record Type: Journal Article
• Authors: Lusardi, Theresa A.; Akula, Kiran K.; Coffman, Shayla Q.; Ruskin, David N.; Masino, Susan A.; Boison, Detlev
• Is Part Of: Neuropharmacology. Volume 99(2015)
• Page Start: 500
• Page End: 509
• Publication Date: 2015-12
• Subjects: TLE -- Acquired epilepsy -- Chemoconvulsant -- Adenosine -- Epigenetics -- DNA methylation; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2015.08.007
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: Epilepsy is a highly prevalent seizure disorder which tends to progress in severity and become refractory to treatment. Yet no therapy is proven to halt disease progression or to prevent the development of epilepsy. Because a high fat low carbohydrate ketogenic diet (KD) augments adenosine signaling in the brain and because adenosine not only suppresses seizures but also affects epileptogenesis, we hypothesized that a ketogenic diet might prevent epileptogenesis through similar mechanisms. Here, we tested this hypothesis in two independent rodent models of epileptogenesis. Using a pentylenetetrazole kindling paradigm in mice, we first show that a KD, but not a conventional antiepileptic drug (valproic acid), suppressed kindling-epileptogenesis. Importantly, after treatment reversal, increased seizure thresholds were maintained in those animals kindled in the presence of a KD, but not in those kindled in the presence of valproic acid. Next, we tested whether a KD can halt disease progression in a clinically relevant model of progressive epilepsy. Epileptic rats that developed spontaneous recurrent seizures after a pilocarpine-induced status epilepticus were treated with a KD or control diet (CD). Whereas seizures progressed in severity and frequency in the CD-fed animals, KD-fed animals showed a prolonged reduction of seizures, which persisted after diet reversal. KD-treatment was associated with increased adenosine and decreased DNA methylation, the latter being maintained after diet discontinuation. Our findings demonstrate that a KD prevented disease progression in two mechanistically different models of epilepsy, and suggest an epigenetic mechanism underlying the therapeutic effects. Highlights: Ketogenic diet (KD) therapy attenuates epileptogenesis and disease progression after epilepsy onset in adult rodents. KD therapy increases adenosine in the brain. KD therapy restores DNA methylation status in epileptic hippocampus, which is maintained after return to normal diet.